ACRS Aclaris Therapeutics Inc

Price (delayed)

$4.64

Market cap

$648.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.56

Enterprise value

$619.38M

?
Relative Growth: Rel. Growth: 30
Relative Strength: Rel. Strength: 93
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 16

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The ...

Highlights
ACRS's equity is up by 39% QoQ
ACRS's gross profit has plunged by 69% YoY but it is up by 50% from the previous quarter
Aclaris Therapeutics's EPS has surged by 65% YoY but it has decreased by 6% QoQ

Key stats

What are the main financial stats of ACRS

ACRS stock price

How has the Aclaris Therapeutics stock price performed over time
Intraday
4.98%
1 week
1.53%
1 month
2.43%
1 year
188.2%
YTD
54.15%
QTD
23.73%

Financial performance

How have Aclaris Therapeutics's revenue and profit performed over time
Revenue
$8.37M
Gross profit
$811,000
Operating income
-$78.48M
Net income
-$69.66M
Gross margin
9.7%
Net margin
-832.6%
ACRS's gross profit has plunged by 69% YoY but it is up by 50% from the previous quarter
The company's revenue has shrunk by 53% YoY but it rose by 7% QoQ
The company's net income rose by 46% YoY but it fell by 7% QoQ
The operating income has increased by 44% YoY but it has decreased by 6% from the previous quarter

Price vs fundamentals

How does ACRS's price correlate with its fundamentals

Growth

What is Aclaris Therapeutics's growth rate over time

Valuation

What is Aclaris Therapeutics stock price valuation
P/E
N/A
P/B
3.5
P/S
71.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
74.03
Aclaris Therapeutics's EPS has surged by 65% YoY but it has decreased by 6% QoQ
ACRS's P/B is 51% above its last 4 quarters average of 2.2 and 15% above its 5-year quarterly average of 2.9
ACRS's equity is up by 39% QoQ
ACRS's P/S is 109% above its last 4 quarters average of 32.5 and 30% above its 5-year quarterly average of 52.2
The company's revenue has shrunk by 53% YoY but it rose by 7% QoQ

Efficiency

How efficient is Aclaris Therapeutics business performance
The ROA has increased by 44% YoY but it has decreased by 7% from the previous quarter
Aclaris Therapeutics's return on invested capital has increased by 43% YoY but it has decreased by 8% QoQ
The company's return on equity rose by 40% YoY but it fell by 8% QoQ
Aclaris Therapeutics's return on sales has decreased by 14% YoY

Dividends

What is ACRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRS.

Financial health

How did Aclaris Therapeutics financials performed over time
Aclaris Therapeutics's total assets has increased by 24% from the previous quarter
Aclaris Therapeutics's quick ratio has increased by 20% QoQ but it has decreased by 18% YoY
ACRS's debt is 100% less than its equity
ACRS's equity is up by 39% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.